symptom management of treatment toxicities in early breast cancer patients frances m. palmieri, rn,...
TRANSCRIPT
Symptom Management of Treatment Toxicities in
Early Breast Cancer Patients
Frances M. Palmieri, RN, MSN, OCNClinical Nurse Specialist
Manager, Multidisciplinary Breast Clinicand Breast Cancer Program
Mayo ClinicJacksonville, FL
Overview
• Introduction to EBC • Taxanes in HER2 Overexpressing Breast
Cancer • Symptom Management and Patient Support
Strategies– Hematologic; Focus on Non-Hematologic
Toxicities:• Fatigue• Chemotherapy induced sensory peripheral
neuropathy, alopecia, arthralgia/myalgia, mucositis and hypersensitivity reactions
EBC = early breast cancer.HER2 = human epidermal growth factor receptor 2.
United States
Deaths per year 40 970
(212 per day )
Diagnoses per year 212 920
(583 per day)
Breast Cancer Statistics
Jemal A et al. CA: A Cancer Journal for Clinicians. 2006; 56(2):106-130
Invasive Early Breast Cancer Demographics
• Incidence increases with age
– Postmenopausal women make up 80% of all patients with BC
• Incidence BC remains high, but mortality rates have declined in the United States– Reflects advances in early detection, diagnosis, and treatment,
such as novel treatment therapies and advanced
imaging/screening
– Digital Mammography or MRI
• 5-year relative survival rates range from 92% for stage IIA disease to 54% for stage IIIB disease
BC = breast cancer; MRI = magnetic resonance imaging. American Cancer Society. Cancer Facts and Figures 2006. http://www.cancer.org. Accessed December 31, 2007.
Different Types of Breast Cancer
• Early stage vs metastatic• HER2+• Hormone receptor positive (ER+, PR+)• Triple negative• Inherited breast cancer
– BRCA1, BRCA2, and other genes• New classifications of BC are being defined
using gene profiling techniques– Luminal, HER2, basal
BRCA1 = breast cancer 1, early onset.BRCA2 = breast cancer 2, early onset.ER+ = estrogen receptor positive.PR+ = progesterone receptor positive.Trastuzumab [prescribing information]. South San Francisco, CA: Genentech, Inc; 2006
Breast Cancer Subtypes by Gene Profiling
• Normal-like
• Luminal-like– A– B
• ERBB2
• Basal-like
Good prognosisER+
Bad prognosis
ER+ or ER-
ER-, PR-, HER2-
ER- = estrogen receptor negative; ERBB2 = v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian); PR - = progesterone receptor positive.Pegram et al. Cancer Treat Res. 2000;103:57. Romond et al. N Engl J Med. 2005; 353:1673.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™; 2006.Goldhirsch et al. 2005.
Prognostic Factors
Risk factors of BC recurrence:
• Tumor size
• Nodal status
• Grade
• Hormone receptor status
• Age of patient (35 yo)
• HER2/neu oncogene overexpression
Recent Development Timeline: Breast Cancer Chemotherapy
• Before anthracyclines– CMF, CMFVP
• With anthracyclines– Combinations: AC, FAC, AVCMF, FEC, CEF– Sequence and alternating– Dose intensity, dose density, HDCT
• Taxanes (paclitaxel/docetaxel)– Sequential monotherapy– Combinations– Biologic modifiers (trastuzumab, bevacizumab)– Integration in chemotherapy strategies
1970s1970s
1980s1980s
1990s1990s
2000 +2000 +AC = doxorubicin/cyclophosphamide; AVCMF = doxorubicin, vincristine, cyclophosphamide, methotrexate, and fluorouracil; CEF = cyclophosphamide, epirubicin, and fluorouracil; CMF = cyclophosphamide, methotrexate, and fluorouracil; CMFVP = cyclophosphamide, methotrexate, fluorouracil, vincristine, and prednisone; FAC = fluorouracil, doxorubicin, and cyclophosphamide; FEC = flourouracil, epirubicin, and cyclophosphamide; HDCT = high-dose chemotherapy with stem-cell support.Giordano SH et al. Cancer. 2004;100:44-52.
Hematologic Toxicities and Management
• Neutropenia: most common hematologic toxicity
• ASCO guidelines 2006 for prophylactic CSFs strategic guide– CSFs reserved for patients considered at high risk for FN
defined as ≥20% risk, or special circumstances—bone marrow compromise
– Or after a documented occurrence of FN or prolonged period of neutropenia in an earlier cycle of chemotherapy
• Especially if excessive dose reductions or delay in chemo
ASCO = American Society of Clinical Oncology.CSF = colony stimulating factor.FN = febrile neutropenia.ASCO. ASCO Guidelines. http://www.asco.org. Accessed December 31, 2006.
Overview
• Introduction to EBC
• Taxanes in HER2 Overexpressing Breast Cancer
• Symptom Management and Patient Support Strategies– Hematological Toxicities– Nonhematological Toxicities:
• Chemotherapy induced sensory peripheral neuropathy, fatigue, alopecia, arthralgia/myalgia, hypersensitivity reactions, nausea and vomiting, mucositis, and cardiac dysfunction
NonhematologicPeripheral Neurotoxicity
• Caused by peripheral neurodegeneration– Damage to sensory axons and myelin sheath
• Presents with loss of sensation—may progress to weakness and motor changes– Numbness, tingling, or burning pain
• Most distal to medial axon effects
– Bilateral, stocking-glove distribution
– Can be cumulative
– Short and long term symptoms
Wickham R. Clini J Oncol Nurs. 2007;11: 361-376.
Diagnostic StrategiesChemotherapy Induced NeuropathyTest Comments
Assessment of symptoms and clinical examination
Inter- and intra- observer variation
Vibration threshold Simple, non-invasive, and easily repeated but less sensitive than a clinical assessment
Monofilament test
Jebsen test of hand function
Grooved Pegboard test
Overall evaluation of neurologic function
Needs valuation in chemotherapy-induced neuropathy
Nerve conduction study
Needle electromyography
Objective evidence of neuropathy
Needs more study for sensitivity and specificity
Lee JJ, Swain SM. J Clin Oncol. 2006;24:1633-1642.
Careful Assessment and History
• Assess factors increasing risk, mobility, self-care, and fine-motor skill abilities – Careful history, writing, buttoning; functional impairment of
ADLs – Accurate assessment is key to decision making regarding dose
modifications, length of administration time, and discontinuation
• Teach patients to report any change in status – Numbness, burning, and/or tingling of extremities– “Overadherence” issue
• Manage pain– PT, OT, and/or medications
ADL = activity of daily living; OT = occupational therapy; PT = physical therapy.
Wickham R. Clini J Oncol Nurs. 2007;11:361-376.
Arthralgia/Myalgia
• Incidence – Docetaxel 10%– Paclitaxel 8%– Nab-paclitaxel 7%– Ixabepilone 8%
• Occurs few days post treatment with resolution in 2–6 days
– Shoulder and paraspinal muscles commonly affected
– Prophylactic or treatment analgesics such as ibuprofen, acetaminophen, or narcotics
Wickham R. Clin J Oncol Nurs. 2007;11:361-376. Perez EA et al. J Clin Oncol. 2007;25:3407-3414.Paclitaxel protein-bound [prescribing information]. Schaumburg, IL: American Pharmaceutical Partners, Inc; 2005.Icabepilone [prescribing information]. Princeton, NJ: Bristol Myers Squibb Company; 2007.
Fatigue
• Reported as one of the most problematic side effects over time related to treatment for BC– Adds to the severity of other symptoms of chemotherapy
– Diminishing quality of life, ability to manage self-care
• Symptoms may include– Lethargy—weakness or total lack of energy, malaise
– Sleeplessness
– Anxiety
– Difficulty with concentration, thinking clearly, making decisions
– Muscle pain, other constitutional symptoms
National Comprehensive Cancer Network. Cancer-Related Fatigue Guidelines. http://www.cancersymptoms.org/peripheralneuropathy/overview. Accessed December 31, 2006.
Fatigue
NCCN: Cancer-related fatigue guidelines • Treatment algorithm to identify and treat
fatigue • Patients evaluated using a brief screening
instrument • Evaluate level of distress• Assess if fatigue is interfering with daily
activities or functioning
National Comprehensive Cancer Network. Cancer-Related Fatigue Guidelines. http://www.cancersymptoms.org/peripheralneuropathy/overview. Accessed December 31, 2006.
Fatigue
• Additional interventions that help alleviate fatigue– Correct known causes of fatigue
• Anemia, nutritional deficits, sleep disorders
– Encourage regular exercise– Assess current medications
• Pain, antidepressant and anti-anxiety
– Other lifestyle modifications• Attention-restoring activities
– Psychological counseling – Physical therapy
National Comprehensive Cancer Network. Cancer-Related Fatigue Guidelines. http://www.cancersymptoms.org/peripheralneuropathy/overview. Accessed December 31, 2006.
Hypersensitivity Reactions • Occur in response to antigens that trigger antibody production:
Infrequent but potentially serious reactions • Characterized by facial flush, pruritis, rash, dyspnea with bronchospasm,
and hypotension
• Pre-medication:
• Availability of hypersensitivity reaction guidelines/protocol at infusion site
• Appropriate equipment and medications – epinephrine, corticosteriods, antihistamines, bronchodilators
Paclitaxel, Docetaxel Dexamethasone, Oral/IV H1 and H2 blockers
Docetaxel Additional Dexamethasone premed, Dexamethasone, Oral/IV H1 and H2 blockers
Nab-paclitaxel None (No solvent)
Ixabepilone Oral/IV H1 and H2 blockers (↓ Total dose of Cremophor EL)
Perez EA et al. J Clin Oncol. 2007;25:3407-3414.Docetaxel [prescribing information]. Bridgewater, NJ: Sanofi-Aventis, LLC; 2007.Icabepilone [prescribing information]. Princeton, NJ: Bristol Myers Squibb Company; 2007.Paclitaxel protein-bound [prescribing information]. Schaumburg, IL: American Pharmaceutical Partners, Inc; 2005.
Nausea and Vomiting Common Toxicity Criteria v 3
Adverse Event
Nausea Vomiting
Grade 1 Loss of appetite without alteration in eating habits
1 episode in 24 hrs
Grade 2 Oral intake decreased without significant weight loss,
dehydration or malnutrition; IV fluids indicated <24 hrs
2–5 episodes in 24 hrs; IV fluids indicated <24 hrs
Grade 3 Inadequate oral caloric or fluid intake; IV fluids, tube feedings, or
TPN indicated >24 hrs
≥6 episodes in 24 hrs; IV fluids, or TPN indicated
≥24 hrs
Grade 4 Life-threatening
consequencesLife-threatening
consequences
Grade 5 Death Death
IV = intravenous; TPN = total parenteral nutrition.
Mucositis
• Cause: Destroyed cell proliferation throughout GI tract
• Interventions– Good oral hygiene and soft toothbrush– Soda mouthwash– Adequate fluid intake– Treat with magic mouthwash p.r.n.
Cardiac Monitoring
• Thorough baseline cardiac assessment, – Including history, physical examination, and
assessment of LVEF by echocardiogram or MUGA scan
• Frequent monitoring for left ventricular function during and after trastuzumab treatment
• More frequent monitoring should be employed if treatment is withheld in patients who develop significant left ventricular cardiac dysfunction
LVEF = left ventricular ejection fraction.MUGA = multigated acquisition.
Patient Teaching
• Create environment in which patients are likely to report symptoms– Promote self-care measures
• www.cancersymptoms.org• www.cancersupportivecare.com• www.chemocare.com• www.canceradocacy.org
Wickham R. Clin J Oncol Nurs. 2007;11:361-376. Armstrong, 2005,ONF
Educational Considerations
• Teaching patients to manage the effects of treatment is demonstrated to decrease symptom distress
• Oncology nursing role to provide the education needed to assist patients in performing effective self-care